By: Adam Feuerstein | 05/12/14 - 06:24 PM EDT
Telik never recovered from
hiding the premature deaths of ovarian cancer patients treated with its experimental drug Telcyta. Following the
serious ethical lapse in 2007, Telik became a biotech pariah, ignored by scientists and investors. Telik's top executives, the husband-and-wife team Michael Wick and Gail Brown, spent the next seven years cashing paychecks paid for by long-gone shareholders.
With the money finally gone, Telik is also disappearing. On Monday, the company announced a reverse merger with privately held Mabvax Therapeutics. When the deal closes, MabVax stockholders will own 85% of the combined companies, which will also be run by MabVax management and retain the MabVax name. Telik shareholders will own 15% and Wick keeps a seat on the board.
MabVax is developing cancer vaccines, with two products targeting sarcoma and ovarian cancer enrolling patients in proof-of-concept phase II studies.
TELK data by YCharts
09/16/14 - 01:04 PM EDT
09/15/14 - 10:19 AM EDT
09/12/14 - 09:43 AM EDT
09/11/14 - 01:23 PM EDT
09/10/14 - 03:37 PM EDT
09/18/14 - 09:05 AM EDT
09/17/14 - 12:44 PM EDT
09/17/14 - 09:30 AM EDT
09/16/14 - 12:11 PM EDT
09/15/14 - 10:40 AM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.